United States · Markets & Finance · The Motley Fool

Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?

Published by The Motley Fool · United States 8 h ago

BioNTech announced that it was stopping a Phase 2 clinical trial for autogene cevumeran, which it was testing as an adjuvant treatment for certain patients with colorectal cancer.…

Read the full article on The Motley Fool Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.fool.com)

Also worth reading

CNBC

Bessent warns Zelenskyy to 'be very careful' about claims U.S. is throttling Starlink

NYT Business

What Is Starshield, SpaceX’s Military-Grade Satellite Internet Service Ukraine Relies On?

TechCrunch

Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?

Share

Also worth reading

Bessent warns Zelenskyy to 'be very careful' about claims U.S. is throttling Starlink

What Is Starshield, SpaceX’s Military-Grade Satellite Internet Service Ukraine Relies On?

Everyone’s watching the Elizabeth Holmes documentary ‘You Can See Everything’

The Nuclear Power Shortcut That Could Add Gigawatts to the U.S. Grid

Anthropic commits billions to a 'public benefit fund'

‘Street Fighter’ hits $31M in box office debut as moviegoing jumps 48%